论文部分内容阅读
目的:分析冠心病心力衰竭患者实施美托洛尔联合曲美他嗪疗法的效果。方法:调查对象从2012年1月-2015年9月我院接收冠心病心力衰竭患者中挑选,将200例平均分成不同组:100例对照组患者根据对症实施对症疗法,100例研究组则于对照组疗法上实施美托洛尔联合曲美他嗪疗法,评定治疗后的效果。结果:研究组患者预后疾病好转率为97.0%(97/100),高于88.0%(88/100)的对照组,统计学有区别,P<0.05;研究组患者预后的血压(收缩压、舒张压)、心率指标水平低于对照组,统计学有区别,P<0.05。结论:临床针对冠心病心力衰竭患者实施美托洛尔联合曲美他嗪疗法作用突出,可改善血压指标,提高心功能等级,增强疗效,值得学习。
Objective: To analyze the effect of metoprolol combined with trimetazidine in patients with coronary heart disease and heart failure. Methods: The subjects were selected from January 2012 to September 2015 in our hospital to receive heart failure patients with coronary heart disease, the average of 200 were divided into different groups: 100 patients in the control group according to the symptomatic symptomatic therapy, 100 patients in the study group The control group was treated with metoprolol combined with trimetazidine therapy to assess the effect after treatment. Results: The improvement rates of prognosis of the study group were 97.0% (97/100), higher than 88.0% (88/100) in the control group, with statistical significance (P <0.05). The prognosis of study group patients with blood pressure (systolic blood pressure, Diastolic pressure), heart rate index lower than the control group, statistically significant difference (P <0.05). Conclusion: The clinical effect of metoprolol combined with trimetazidine in patients with heart failure of coronary heart disease is prominent, which can improve the blood pressure index, improve the level of cardiac function and enhance the curative effect. It is worth learning.